[Home ] [Archive]    
:: Main :: About :: Current Issue :: Archive :: Search :: Submit :: Contact ::
Main Menu
Home::
IJRR Information::
About the Journal
Editorial Board
Keywords
For Authors::
Aims and Scope
Call for Papers
Submission Instructions
For Reviewers::
Referee page
Subscription::
Subscription Form
News & Events::
Journal News
Web Mail::
::
Search in website

Advanced Search
..
Receive site information
Enter your Email in the following box to receive the site news and information.
..
ISSN
Hard Copy 2322-3243
Online 2345-4229
..
Online Submission
Now you can send your articles to IJRR office using the article submission system.
..

AWT IMAGE

AWT IMAGE
:: Volume 22, Issue 4 (10-2024) ::
Int J Radiat Res 2024, 22(4): 947-954 Back to browse issues page
The efficacy and safety of transcatheter arterial chemoembolization combined with lenvatinib plus radiotherapy in the treatment of hepatocellular carcinoma: a meta-analysis
X. Wang , X. Xie , G. Zhang , B. Wang
Department of Intervention, Xinchang County People's Hospital, Shaoxing 312500, Zhejiang Province, China , fengshijia18@163.com
Abstract:   (579 Views)
Background: transcatheter arterial chemoembolization (TACE) is the standard treatment for advanced and unresectable hepatocellular carcinoma (HCC) patients. Lenvatinib (LVTN) is one of the novel oral antiangiogenic drugs demonstrating promising application prospects, which has been widely concerned and studied. This work was to systematically analyze efficacy and safety of TCAE combined with LVTN plus radiotherapy (RT) on HCC through the meta-analysis. Materials and Methods: a comprehensive search was conducted on PubMed, Web of Science, Embase, and The Cochrane Library databases from January 2000 to the present to identify studies examining the effectiveness and safety of combining TCAE with LVTN and RT for the treatment of HCC. Relevant literature was screened, and essential information along with evaluation indicators were extracted for analysis. RevMan5.3 was employed for quality assessment and meta-analysis of the included studies, and forest maps (FMs) were drawn. Results: five studies were included. Meta-analysis showed that TCAE combined with LVTN plus RT enhanced the total objective response rate (ORR) of HCC (OR = 3.16, 95%CI = 1.37-7.32, P < 0.05). TCAE combined with LVTN plus RT enhanced the total survival (OS) rate of HCC patients (OR = 2.01, 95%CI=1.30-3.12, P < 0.05). TCAE combined with LVTN plus RT could reduce the diarrhea rate greatly (OR = 2.84, 95%CI = 1.16-6.96, P< 0.05). However, no observable difference was found in the incidence of hypertension caused by TCAE combined with LVTN plus RT (OR = 2.39, 95%CI = 0.62-9.23, P > 0.05). Conclusion: LVTN combined with TACE had superior efficacy on HCC compared with non-LVTN combined with TCAE, but the related side effects (SEs) may affect the scope of application and the quality of life of patients.
Keywords: lenvatinib, chemoembolization, hepatocellular, treatment outcome, meta-analysis.
Full-Text [PDF 941 kb]   (137 Downloads)    
Type of Study: Original Research | Subject: Radiation Biology
References
1. Kirstein MM, Wirth TC (2020) Multimodal treatment of hepatocellular carcinoma. Der Internist, 61: 164-169. [DOI:10.1007/s00108-019-00722-x] [PMID]
2. Liu R, Zhu LL, Yu CY, et al. (2021) Quantitative evaluation of the compatibility effects of aidi injection on the treatment of hepatocellular carcinoma using targeted metabolomics: a new strategy on the mechanism study of an anticancer compound in traditional Chinese medicine. World Journal of Traditional Chinese Medicine, 7(1): 111-119. [DOI:10.4103/wjtcm.wjtcm_86_20]
3. Fu Z, Li X, Zhong J, et al. (2021) Lenvatinib in combination with transarterial chemoembolization for treatment of unresectable hepatocellular carcinoma (uHCC): a retrospective controlled study. Hepatology international, 15: 663-675. [DOI:10.1007/s12072-021-10184-9] [PMID] []
4. Chen Z, Xie H, Hu M, et al. (2020) Recent progress in treatment of hepatocellular carcinoma. American journal of cancer research, 10(9): 2993.
5. Wallace MC, Preen D, Jeffrey GP, et al. (2015) The evolving epidemiology of hepatocellular carcinoma: a global perspective. Expert review of gastroenterology & hepatology, 9(6): 765-779. [DOI:10.1586/17474124.2015.1028363] [PMID]
6. Han Y, Cao G, Sun B, et al. (2021) Regorafenib combined with transarterial chemoembolization for unresectable hepatocellular carcinoma: a real-world study. BMC gastroenterology, 21: 1-10. https://doi.org/10.21203/rs.3.rs-209208/v1 [DOI:10.1186/s12876-021-01967-3]
7. Llovet JM, Vogel A, Madoff DC, Xie DY, Ren ZG, Zhou J (2022) Randomized phase 3 LEAP-012 study: transarterial chemoembolization with or without lenvatinib plus pembrolizumab for intermediate-stage hepatocellular carcinoma not amenable to curative treatment. Cardiovascular and interventional radiology, 45(4): 405-412. [DOI:10.1007/s00270-021-03031-9] [PMID] []
8. Jindal A, Thadi A, Shailubhai K (2019) Hepatocellular carcinoma: etiology and current and future drugs. Journal of clinical and experimental hepatology, 9(2): 221-232. [DOI:10.1016/j.jceh.2019.01.004] [PMID] []
9. Xie DY, Ren ZG, Zhou J, et al. (2020) 2019 Chinese clinical guidelines for the management of hepatocellular carcinoma: updates and insights. Hepatobiliary surgery and nutrition, 9(4): 452. [DOI:10.21037/hbsn-20-480] [PMID] []
10. Haber PK, Puigvehí M, Castet F, et al. (2021) Evidence-based management of hepatocellular carcinoma: systematic review and meta-analysis of randomized controlled trials (2002-2020). Gastroenterology, 161(3): 879-898. [DOI:10.1053/j.gastro.2021.06.008] [PMID]
11. Xu YJ, Lai ZC, He MK, et al. (2021) Toripalimab combined with hepatic arterial infusion chemotherapy versus lenvatinib for advanced hepatocellular carcinoma. Technology in Cancer Research & Treatment, 20: 15330338211063848. [DOI:10.1177/15330338211063848] [PMID] []
12. Chakraborty E, Sarkar D (2022) Emerging therapies for hepatocellular carcinoma (HCC). Cancers, 14(11): 2798. [DOI:10.3390/cancers14112798] [PMID] []
13. Cai M, Huang W, Huang J, et al. (2022) Transarterial chemoembolization combined with lenvatinib plus PD-1 inhibitor for advanced hepatocellular carcinoma: a retrospective cohort study. Frontiers in immunology, 13: 848387. [DOI:10.3389/fimmu.2022.848387] [PMID] []
14. Xing R, Gao J, Cui Q, et al. (2021) Strategies to improve the antitumor effect of immunotherapy for hepatocellular carcinoma. Frontiers in immunology, 12: 783236. [DOI:10.3389/fimmu.2021.783236] [PMID] []
15. Khan AR, Wei X, Xu X (2021) Portal vein tumor thrombosis and hepatocellular carcinoma-the changing tides. Journal of Hepatocellular Carcinoma, 1089-1115. [DOI:10.2147/JHC.S318070] [PMID] []
16. Wang J, Li J, Tang G, et al. (2021) Clinical outcomes and influencing factors of PD‑1/PD‑L1 in hepatocellular carcinoma. Oncology Letters, 21(4): 1-1. [DOI:10.3892/ol.2021.12540] [PMID]
17. Fu Z, Li X, Zhong J, et al. (2021) Lenvatinib in combination with transarterial chemoembolization for treatment of unresectable hepatocellular carcinoma (uHCC): a retrospective controlled study. Hepatology international, 15: 663-675. [DOI:10.1007/s12072-021-10184-9] [PMID] []
18. Chen S, Wu Z, Shi F, et al. (2021) Lenvatinib plus TACE with or without pembrolizumab for the treatment of initially unresectable hepatocellular carcinoma harbouring PD-L1 expression: a retrospective study. Journal of Cancer Research and Clinical Oncology, 1-11. [DOI:10.1007/s00432-021-03767-4] [PMID] []
19. Odagiri N, Hai H, Thuy LTT, et al. (2020) Early change in the plasma levels of circulating soluble immune checkpoint proteins in patients with unresectable hepatocellular carcinoma treated by lenvatinib or transcatheter arterial chemoembolization. Cancers, 12(8): 2045. [DOI:10.3390/cancers12082045] [PMID] []
20. Ding X, Sun W, Li W, et al. (2021) Transarterial chemoembolization plus lenvatinib versus transarterial chemoembolization plus sorafenib as first‐line treatment for hepatocellular carcinoma with portal vein tumor thrombus: a prospective randomized study. Cancer, 127(20): 3782-3793. [DOI:10.1002/cncr.33677] [PMID]
21. Ando Y, Kawaoka T, Amioka K, et al. (2021) Efficacy and safety of lenvatinib-transcatheter arterial chemoembolization sequential therapy for patients with intermediate-stage hepatocellular carcinoma. Oncology, 99(8): 507-517. [DOI:10.1159/000515865] [PMID]
22. Zhu XD, Tang ZY, Sun HC (2020) Targeting angiogenesis for liver cancer: past, present, and future. Genes & Diseases, 7(3): 328-335. [DOI:10.1016/j.gendis.2020.03.010] [PMID] []
23. Zhang JX, Chen YX, Zhou CG, et al. (2022) Transarterial chemoembolization combined with lenvatinib versus transarterial chemoembolization combined with sorafenib for unresectable hepatocellular carcinoma: A comparative retrospective study. Hepatology Research, 52(9): 794-803. [DOI:10.1111/hepr.13801] [PMID]
24. Zhang Z, Wu Y, Zheng T, et al. (2022) Efficacy of transarterial chemoembolization combined with molecular targeted agents for unresectable hepatocellular carcinoma: a network meta-analysis. Cancers, 14(15): 3710. [DOI:10.3390/cancers14153710] [PMID] []
25. Xiang YJ, Wang K, Yu HM, et al. (2022) Transarterial chemoembolization plus a PD‐1 inhibitor with or without lenvatinib for intermediate‐stage hepatocellular carcinoma. Hepatology Research, [DOI:10.1111/hepr.13773] [PMID]
26. 52(8): 721-729.
27. Ahmet BD, Omer C, Cenk S, et al. (2022) Ensotatin and VEGF expression in hepatocellular carcinoma: A clinical study. ACTA MEDICA MEDITERRANEA, 38(3): 1523-1527.
28. Yu L, Liu Q, Huo J, et al. (2020) Cancer-associated fibroblasts induce immunotherapy resistance in hepatocellular carcinoma animal model. Cellular and Molecular Biology, 66(2): 36-40. [DOI:10.14715/cmb/2020.66.2.5]
29. Wu JY, Wu JY, Li YN, et al. (2022) Lenvatinib combined with anti-PD-1 antibodies plus transcatheter arterial chemoembolization for neoadjuvant treatment of resectable hepatocellular carcinoma with high risk of recurrence: A multicenter retrospective study. Frontiers in Oncology, 12: 985380. [DOI:10.3389/fonc.2022.985380] [PMID] []
30. Eugen K (2020) Current treatment options for hepatocellular carcinoma. Klinicka Onkologie: Casopis Ceske a Slovenske Onkologicke Spolecnosti, 33(Supplementum 3): 20-25. [DOI:10.14735/amko20203S20] [PMID]
31. Teng Y, Ding X, Li W, et al. (2022) A retrospective study on therapeutic efficacy of transarterial chemoembolization combined with immune checkpoint inhibitors plus lenvatinib in patients with unresectable hepatocellular carcinoma. Technology in Cancer Research & Treatment, 21: 15330338221075174. [DOI:10.1177/15330338221075174] [PMID] []
32. Luo F, Li M, Ding J, et al. (2021) The progress in the treatment of hepatocellular carcinoma with portal vein tumor thrombus. Frontiers in Oncology, 11: 635731. [DOI:10.3389/fonc.2021.635731] [PMID] []
33. Li X, Fu Z, Chen X, et al. (2022) Efficacy and safety of lenvatinib combined with PD-1 inhibitors plus TACE for unresectable hepatocellular carcinoma patients in China real-world. Frontiers in Oncology, 12: 950266. [DOI:10.3389/fonc.2022.950266] [PMID] []
34. Sun B, Zhang L, Sun T, et al. (2022) Safety and efficacy of lenvatinib combined with camrelizumab plus transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: A two-center retrospective study. Frontiers in Oncology, 12: 982948. [DOI:10.3389/fonc.2022.982948] [PMID] []
35. Cao F, Yang Y, Si T, et al. (2021) The efficacy of TACE combined with lenvatinib plus sintilimab in unresectable hepatocellular carcinoma: a multicenter retrospective study. Frontiers in Oncology, 11: 783480. [DOI:10.3389/fonc.2021.783480] [PMID] []
36. Yang X, Xu H, Zuo B, et al. (2021) Downstaging and resection of hepatocellular carcinoma in patients with extrahepatic metastases after stereotactic therapy. Hepatobiliary Surgery and Nutrition, 10(4): 434. [DOI:10.21037/hbsn-21-188] [PMID] []
37. Luo J, Huang Z, Wang M, et al. (2022) Prognostic role of multiparameter MRI and radiomics in progression of advanced unresectable hepatocellular carcinoma following combined transcatheter arterial chemoembolization and lenvatinib therapy. BMC gastroenterology, 22(1): 108. [DOI:10.1186/s12876-022-02129-9] [PMID] []
38. Ji X, Xu Z, Sun J, et al. (2023) Lenvatinib with or without stereotactic body radiotherapy for hepatocellular carcinoma with portal vein tumor thrombosis: a retrospective study. Radiation Oncology, 18(1): 1-12. https://doi.org/10.21203/rs.3.rs-2452311/v1 [DOI:10.1186/s13014-023-02270-z]
39. Goh MJ, Oh JH, Park Y, et al. (2021) Efficacy and safety of lenvatinib therapy for unresectable hepatocellular carcinoma in a real-world practice in Korea. Liver Cancer, 10(1): 52-62. [DOI:10.1159/000512239] [PMID] []
40. Zhang A, Duan X, Wang Q (2023) Stereotactic Body Radiotherapy versus Lenvatinib for Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis: A Propensity Score Analysis.
41. Hiraoka A, Tanizawa Y, Huang YJ, et al. (2021) Association of Albumin-Bilirubin Grade and sequential treatment with standard systemic therapies for advanced hepatocellular carcinoma: a retrospective cohort study using a Japanese Administrative Database. Drugs-Real World Outcomes, 8: 301-314. [DOI:10.1007/s40801-021-00245-8] [PMID] []
42. Zhang M, Lai W, Zhang J, et al. (2022) Efficacy Investigation of TACE Combined with Lenvatinib and Sintilimab in Intermediate-Stage Hepatocellular Carcinoma. Disease markers, 2022. [DOI:10.1155/2022/6957580] [PMID] []
Send email to the article author

Add your comments about this article
Your username or Email:

CAPTCHA

XML     Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Wang X, Xie X, Zhang G, Wang B. The efficacy and safety of transcatheter arterial chemoembolization combined with lenvatinib plus radiotherapy in the treatment of hepatocellular carcinoma: a meta-analysis. Int J Radiat Res 2024; 22 (4) :947-954
URL: http://ijrr.com/article-1-5773-en.html
Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Volume 22, Issue 4 (10-2024) Back to browse issues page
International Journal of Radiation Research
Persian site map - English site map - Created in 0.05 seconds with 50 queries by YEKTAWEB 4710